Cargando…
Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome
Nonalcoholic steatohepatitis (NASH) is associated with obesity, metabolic syndrome, and dysbiosis of the gut microbiome. Cholecystokinin (CCK) is released by saturated fats and plays an important role in bile acid secretion. CCK receptors are expressed on cholangiocytes, and CCK-B receptor expressio...
Autores principales: | Gay, Martha D., Cao, Hong, Shivapurkar, Narayan, Dakshanamurthy, Sivanesan, Kallakury, Bhaskar, Tucker, Robin D., Kwagyan, John, Smith, Jill P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836891/ https://www.ncbi.nlm.nih.gov/pubmed/35163821 http://dx.doi.org/10.3390/ijms23031899 |
Ejemplares similares
-
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma
por: Shivapurkar, Narayan, et al.
Publicado: (2023) -
4119 Cholecystokinin (CCK) Receptor Antagonist Reverses Nonalcoholic Steatohepatitis (NASH) by Reducing Hepatic Macrophages and Inflammatory Cytokines
por: Gay, Martha, et al.
Publicado: (2020) -
A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma
por: Tucker, Robin D., et al.
Publicado: (2019) -
Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment
por: Hsu, Christine C., et al.
Publicado: (2022) -
Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non‐alcoholic Steatohepatitis
por: Rabiee, Atoosa, et al.
Publicado: (2022)